Sedivention Raises $3.2M Seed Round to Advance Obesity Therapy

Why It Matters

If successful, Sedivention’s therapy could dramatically lower the cost and risk of obesity treatment, opening outpatient care to millions of patients. It also positions the company at the forefront of next‑generation medtech solutions targeting chronic metabolic disease.

Key Takeaways

• Sedivention raised €2.9M (~$3.2M) seed funding.
• Therapy uses cryoablation via balloon catheter to target vagus nerve.
• One-time outpatient procedure aims to replace bariatric surgery.
• Prototype ready; first‑in‑human trial planned with new capital.
• Addresses >1 billion global obesity patients seeking minimally invasive care.

Pulse Analysis

The global obesity epidemic now affects more than a billion adults, driving unprecedented demand for effective, affordable interventions. Traditional bariatric surgery, while clinically proven, carries significant operative risk, high costs, and limited accessibility, especially in emerging markets. Pharmacologic options often require lifelong adherence and can be hampered by side‑effects or diminishing efficacy. Health systems worldwide are therefore seeking solutions that combine durability with minimal invasiveness, a gap that has spurred a wave of innovation in medical devices and interventional therapies. These pressures are accelerating investment in novel interventional modalities.

Sedivention, a Berlin‑based medtech venture, is tackling this challenge with a one‑time, outpatient cryoablation procedure delivered through a balloon catheter similar to a gastroscope. By precisely freezing segments of the vagus nerve, the therapy aims to blunt hunger signaling, offering sustained appetite reduction without implants or chronic medication. The company has already built a functional prototype and demonstrated safety in preclinical studies. The recent €2.9 million seed round—approximately $3.2 million—will finance a first‑in‑human trial, data collection, and the regulatory groundwork needed to bring the device to market.

If clinical outcomes confirm the hypothesized appetite control, Sedivention could disrupt a market dominated by costly surgeries and long‑term drug regimens, delivering a cost‑effective, scalable solution for health insurers and providers. The funding mix—venture capital, strategic medtech investors, and high‑tech funds—signals confidence in the technology’s commercial potential and aligns with broader industry trends toward minimally invasive, procedure‑based therapies. Successful regulatory clearance would also pave the way for similar neuro‑modulation platforms targeting metabolic disorders, positioning the company as a pioneer in the next generation of obesity treatment.

Deal Summary

German medtech startup Sedivention, developing a minimally invasive cryoablation obesity treatment, raised €2.9M ($3.2M) in a seed round led by bmp Ventures and IBG funds, with participation from HTGF and Cambridge Ventures. The funding will support product development, first‑in‑human studies, and regulatory preparation.